London · Delayed Price · Currency is GBP · Price in GBX Animalcare Group Earnings Call Transcripts
Fiscal Year 2026
-
Ambitious plans target GBP 150 million revenue by 2030, leveraging organic growth, M&A, and innovation. Margin and EBITDA improvements are driven by product mix, supply chain optimization, and commercial excellence, while a robust R&D pipeline and strategic acquisitions support expansion in key markets.
Fiscal Year 2025
-
Revenue grew 18.3% year-over-year, driven by Randlab's strong integration and organic performance. Margins and cash flow improved, with robust investment in R&D and a healthy M&A pipeline. Regulatory and FX headwinds were managed, and the outlook remains positive.
Fiscal Year 2024
-
Strong H1 organic growth was driven by flagship products and robust performance in production and equine segments. Significant cash from disposals is fueling an active M&A pipeline, with a focus on expanding geographic reach and product innovation. Confident outlook for H2, with continued investment in operational excellence and new product launches.
-
H1 2024 saw 5% organic revenue growth, improved gross margins, and strong cash generation, driven by key products and strategic disposals. The business is well-positioned for further M&A and new product launches, with FY 2024 results expected in line with expectations.